85%Confidence
0Views
FDASource
2026-04-01Date
Summary
Cipla's Nilotinib Capsules recall due to stability failures indicates potential quality control issues in manufacturing processes, which could impact patient safety and regulatory compliance. This may lead to increased scrutiny from the FDA and potential supply disruptions for this oncology medication.
Actionable: Monitor Cipla's manufacturing quality metrics and consider diversifying supplier sources for nilotinib capsules.
AI Confidence: 85%
Data Points
firmCipla USA, Inc.
classificationClass III
statusOngoing
distributionU.S.A. Nationwide
productNilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now